FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
|Slideshows|November 29, 2018
Pre-exposure HIV Prophylaxis Works
Author(s)Gregory M. Weiss, MD
Further hope for prevention of transmission as the search for a cure continues.
Advertisement
Advertisement
Related to this article
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
5